Highlights
Profile claimed by owner
About
AI-based Platform to Produce Human Tissue for Cell-based Therapies
Somite.ai is aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle as it enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders.
Identity
| Name | Somite.ai |
|---|---|
| Slug | somite-ai |
| Type / kind | startup |
| Source _id | xwpjB2KPGf5AMICcbD4lvD4AJ9nBeaExNFv4iLpZ49EhS6GiaeGZAk |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ address | Israel |
Web & social
| Website | https://www.cellularintelligence.com |
|---|---|
| https://www.linkedin.com/company/98835010 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business models
B2C
Tags
artificial-intelligencecell-therapystem-cells
Funding
| Total raised | $57.5M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}